Nouveau Medicament Private Limited - Company Profile

It is a pharma private limited company based in Chennai, Tamil Nadu, India, established in 2001.
2001 Chennai, Tamil Nadu, India Active
Last Updated:
Access Report
About Nouveau Medicament Private Limited

Nouveau Medicament Private Limited, a active private limited company, was established on 17 April 2001 in Chennai, Tamil Nadu, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24231TN2001PTC046971. Registered under ROC Roc Chennai. it is unlisted. It has an authorized capital of ₹4.10 Cr and a paid-up capital of ₹1.48 Cr.

It upholds a compliant status. Employing 278 professional, Its leadership includes Uma Ramaswamy Iyer (Whole-Time Director), Bhagyalakshmi Gowrishankar (Whole-Time Director), Raamganesh Samakkulam (Managing Director). Past directors included Ramaswamy Samakkulam Ramalingam Iyer, Uma Ramaswamy Iyer, Bhagyalakshmi Gowrishankar. It holds no open charges and ₹0.62 M settled loans. Its latest AGM occurred on 29 September 2025, with the balance sheet filed on 31 March 2025. It is based at New No.: 720, Anna Salai , Nandanam,, Chennai, Tamil Nadu, 600035.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24231TN2001PTC046971

  • Registration Number

    046971

  • Incorporation Date

    17 April 2001

  • Authorized Capital

    ₹4.10 Cr

  • Paid-Up Capital

    ₹1.48 Cr

  • ROC Code

    Roc Chennai

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 4.10 Cr
  • Paid Up Capital ₹ 1.48 Cr
  • Company Age 24 Year, 10 Months
  • Last Filing with ROC 31 Mar 2025
  • Satisfied Charges ₹ 0.62 M
  • Revenue Growth **** -9.62%
  • Profit Growth **** -65.95%
  • Ebitda **** -19.47%
  • Net Worth 3.82%
  • Total Assets **** 1.58%
Company report

Nouveau Medicament Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Nouveau Medicament Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Nouveau Medicament Private Limited?
Current Directors
Name Designation Appointment Date Status
Uma Ramaswamy Iyer Whole-Time Director 17 Apr 2001 Current
Bhagyalakshmi Gowrishankar Whole-Time Director 23 Feb 2011 Current
Raamganesh Samakkulam Managing Director 02 Mar 2009 Current
Ramanan Kalyanavenkita Ramalingam Whole-Time Director 02 Mar 2009 Current
Neeraja Ramakrishnan Director 02 Mar 2009 Current
Karthikraman Samakulam Whole-Time Director 02 Mar 2009 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Director 23 Jan 2014 Past
Pramod Abcsdd Director 23 Jan 2014 Past
Pramod Abcsdd Director 23 Jan 2014 Past
Pramod Abcsdd Additional Director 27 Jul 2009 Past
Pramod Abcsdd Additional Director 27 Jul 2009 Past
Pramod Abcsdd Whole-Time Director 01 Sep 2022 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Nouveau Medicament.

Nouveau Medicament Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.62% decrease. The company also saw a substantial fall in profitability, with a 65.95% decrease in profit. The company's net worth moved up by a moderate rise of 3.82%.

Nouveau Medicament revenue growth over time
Nouveau Medicament profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 -9.62%
*******
*******
*******
*******
Revenue from Operations
*******
 5.00%
*******
*******
*******
*******
Total Assets
*******
 1.58%
*******
*******
*******
*******
Profit or Loss
*******
 -65.95%
*******
*******
*******
*******
Net Worth
*******
 3.82%
*******
*******
*******
*******
EBITDA
*******
 -19.47%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Nouveau Medicament?

In 2023, Nouveau Medicament had a promoter holding of 91.39% and a public holding of 8.61%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹0

Satisfied Charges

₹620,000.00

Charges Breakdown by Lending Institutions
  • Uco Bank : 0.06 Cr
Latest Charge Details
Date Lender Amount Status
24 Sep 2004 Uco Bank ₹0.62 M Satisfied

Explore comprehensive loan charge details -

How Many Employees Work at Nouveau Medicament?

Nouveau Medicament has a workforce of 278 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Nouveau Medicament, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nouveau Medicament's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Nouveau Medicament
Recent Activity within the Organization
  • Annual General Meeting

    The activity Nouveau Medicament Private Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records. was completed.

  • Balance Sheet

    Progress on Nouveau Medicament Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chennai. was documented.

  • Charges

    Progress on A charge registered on 24 Sep 2004 via Charge ID 90295109 with Uco Bank was fully satisfied on 11 Oct 2018. was documented.

  • Director Appointment

    Bhagyalakshmi Gowrishankar was appointed as a Whole-time director was appointed as a Whole-time director on 23 Feb 2011 & has been associated with this company since 15 years . was recorded as a recent event.

  • Director Appointment

    Raamganesh Samakkulam was appointed as a Managing Director was appointed as a Managing Director on 02 Mar 2009 & has been associated with this company since 16 years 11 months . was recorded as a recent event.

  • Director Appointment

    Ramanan Kalyanavenkita Ramalingam was appointed as a Whole-time director was appointed as a Whole-time director on 02 Mar 2009 & has been associated with this company since 16 years 11 months . was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Nouveau Medicament Private Limited?

The CIN of Nouveau Medicament Private Limited is U24231TN2001PTC046971.

Where is Nouveau Medicament Private Limited headquartered?

Nouveau Medicament Private Limited is headquartered at New No.: 720, Anna Salai , Nandanam,, Chennai, Tamil Nadu, 600035.

When was Nouveau Medicament Private Limited incorporated?

Nouveau Medicament Private Limited was incorporated on 17 April 2001.

Who are the current directors of Nouveau Medicament Private Limited?

The current directors of Nouveau Medicament Private Limited are

What is the primary industry of Nouveau Medicament Private Limited?

The primary industry of Nouveau Medicament Private Limited is Manufacturing.

Is Nouveau Medicament Private Limited a listed company?

Nouveau Medicament Private Limited is unlisted.

What is the capital structure of Nouveau Medicament Private Limited?

The authorized capital of Nouveau Medicament Private Limited is ₹4.10 Cr, and the paid-up capital is ₹1.48 Cr.

What is the compliance status of Nouveau Medicament Private Limited?

The compliance status of Nouveau Medicament Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available